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Introduction 
As the epidemic of severe and complex obesity worsens, the most successful 
treatment, bariatric surgery, is limited in its availability – less than 1% of those who 
could benefit get this treatment.  In contrast, victims of other life style health 
problems such as liver disease or car crashes related to alcohol are treated.  This 
article explores the clinical- and cost-effectiveness of bariatric surgery and aims to 
estimate how many procedures the National Health Service (NHS) should perform to 
address the epidemic. 
 
Text 
Bariatric surgery is the operative treatment of the stomach and upper 
gastrointestinal tract to facilitate weight loss.  It is more effective and cost effective 
for the treatment of severe obesity than non-surgical measures [1].  Evidence of this 
is shown by 22 randomised controlled trials (RCTs) synthesized in a Cochrane review, 
although findings were limited to two years after surgery. Longer term data are now 
available for two of the included trials and a new study.[2]  All favour surgery.  Non-
randomised data from the Swedish Obese Subjects study (SOS), a long-running 
cohort study of 2,000 operated patients and 2,000 matched controls, supports the 
RCT findings beyond the early time horizon after surgery, with weight loss being 
maintained for 20 years.[3]  The SOS study shows that glycaemic control is improved 
for at least 10 years after surgery, and operated patients were more likely to go into 
glycaemic remission of diabetes than those having non-surgical approaches.  Less 
progression from prediabetes to diabetes was observed.[3]  In the UK a national 
registry of over 3,000 patients with diabetes operated on between 2011 and 2013 
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shows that 65% of patients previously diagnosed with diabetes had acceptable 
glycaemic control not requiring medication.[4]  The Swedish data also indicate that 
in 6,000 operated patients with diabetes there was a 58% reduction in the relative 
risk of dying during an average of only 3.5 years follow up compared to non-
operated matched patients from the registry.[5]  In all the surgical series the average 
weight loss is 25-35% of body weight (usually at least 15kg) after 1 year for patients 
who are severely obese and 15-25% after 20 years.  This is much greater than the 
average 7% weight loss achieved by patients attending intensive lifestyle weight 
management programmes or even using state of the art pharmacotherapy.[6, 7] 
 
Bariatric surgery is cost effective when compared to non-surgical obesity treatments.  
A UK Health Technology Assessment (HTA) report which compared bariatric surgery 
against non-surgical options found that for patients with a body mass index (BMI) of 
40 kg/m2 or more, the incremental cost-effectiveness ratios (ICERs) ranged between 
£2,000 and £4,000 per quality adjusted life year (QALY) gained over a 20-year 
timescale.[9]  This is well below the threshold for cost-effectiveness considered by 
National Institute of Health and Care Excellence (NICE) at £20,000 per QALY.  For 
diabetic patients with a BMI of between ≥30 and <40 kg/m2 this ICER reduced to 
£1,367 per QALY gained.  Regarding maximum willingness to pay, compared with 
non-surgical interventions, if a decision-maker is willing to pay £20,000 for an 
additional QALY, then the probability of surgery being cost-effective over a 20-year 
time horizon was reported as 100%.[9]  Few HTA reports show interventions to be so 
cost-effective.  These low ICERs are in line with other public health interventions 
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such as smoking cessation and using statins for primary prevention of cardiovascular 
disease.[10] 
 
In terms of a macro-level budget impact, the economic analysis for the NICE obesity 
update confirmed that the financial outlay for surgery was justified for the NHS.[11]  
In patients with diabetes for example the costs saved within three years of surgery 
due to reduced prescriptions recoups the initial outlay required for the 
intervention.[12]  Recent data from the Swedish study show that the cost of diabetes 
drugs each year from year 1 to year 15 postoperatively is more than halved in the 
operated patients with diabetes compared to the non-operated group, offsetting the 
initial cost outlay.[13] 
 
There are indirect cost benefits of surgery too.  For example state disability 
allowances are reduced as a result of increased productivity if patients are 
subsequently able to return to paid employment.[14]  This is because surgery leads 
to much improved activity levels: for example, the UK registry data found that only 
28% of patients could climb 3 flights of stairs before surgery and this improved to 
over 72% 12 months later.[4]  Surgery, with appropriate multi-disciplinary support 
during follow up, is therefore recommended to treat people who have become 
victims of severe and complex obesity (Box 1, Figure 1 , Figure 2).  Public health 
measures to reduce incidence are simultaneously recommended, although we do 
not consider them here.  
 
Who is eligible for bariatric surgery? 
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NICE guidance recommends that surgery is considered for individuals with severe 
obesity in whom all non-surgical measures have been tried but in whom adequate 
weight loss has not been achieved or maintained (Box 2).[10]  The person must be 
committed to long-term follow-up and behaviour change. 
 
How many people meet the NICE criteria in the UK? 
In the UK, 1.6 million people have a BMI of at least 40 kg/m2.[15]  There are at least 
half a million people with diabetes and other obesity-related disease with a BMI of 
35 kg/m2 or more, and the lowering of the NICE BMI threshold to 30 kg/m2 for 
diabetes further increases this number to approximately 1 million.  Therefore at 
least 2,600,000 people meet NICE criteria for surgery.[16, 17]  The problem 
continues to escalate as an additional 60,000 people a year reach a BMI of at least 
40 kg/m2.  The last decade has seen a 60% increase to 3.3 million (5% of the adult 
population) in the number of people with type 2 diabetes and 9.5% of adults are 
predicted to have the condition by 2030 (190,000 new patients each year).[18, 19]  
Therefore without action to prevent, but also to treat these diseases, the crisis will 
worsen for the foreseeable future. 
 
Rates of surgery in the UK and elsewhere 
Despite obesity levels increasing, and bariatric surgery being shown to be clinically 
effective and cost effective, the rate of NHS bariatric procedures is falling.  Between 
2011/12 and 2014/15 there was a 31% reduction in the number of operations 
performed, from 8,794 to 6,032.[15, 20]  Provision of surgery in the NHS therefore 
meets much less than 1% of the need.  This is in stark contrast to the rates of surgery 
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provision per capita in many European Union countries.  The UK ranks 13th out of 17 
for countries where the rate is known (0.0087% of the total population or about 
9/100,000), and ranks 6th for the number of operations/capita in the G8 countries 
even though it has the 4th largest economy.[21, 22]  A European country with a 
similar health service, but with lower obesity rates, Sweden, spends slightly more of 
its gross domestic product on healthcare than the UK (9.7% vs 9.1%) yet performs 7-
8 times the number of bariatric operations (70-80 procedures per 100,000 
people).[23, 24]  In North America the rate of surgery is around 40-50/100,000, with 
most of this being in the USA, as limited surgery is performed in Canada.[21] 
 
The low rate of surgery in the UK contrasts with its high prevalence of obesity.  The 
UK has the second highest rate of obesity in Europe, and ranks 6th internationally, 
with 25% of adults being obese and 62% being overweight (BMI over 25 kg/m2) or 
obese.[15, 25]  Given the severity of the problem, the low rates of surgery despite its 
established benefits, and the increased number of diabetes patients eligible on the 
new BMI criteria, it seems urgent to consider what the potential barriers are to 
uptake. 
 
What are the barriers to surgery?  
The reasons appear diverse and occur at all levels (Figure 3).  A key feature is that 
GPs are unable to refer directly to surgical services and a ‘tiered’ service is provided, 
although this is available in many parts of the country.  At the population level (Tier 
1), low calorie foods and exercise are recommended.  Patients themselves, however, 
may have given up with these approaches.  They may be reticent to ask for 
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professional help (Tier 2) because of previous negative responses from health 
professionals, low self-esteem or embarrassment.[26]  Empathetic engagement at 
primary care level (Tier 2) may unintentionally promote these issues, with 
unsolicited advice such as ‘eat less and exercise more’ being harmful.[27]  Although 
GPs receive financial incentives to measure the prevalence of obesity, there are no 
rewards or targets for giving treatment or referring on for specialist help.  NICE 
estimated that about 80% of patients above the BMI thresholds would be medically 
and psychologically suitable for surgery.  About 10% of these might wish to pursue 
this option.[28]   
 
If a GP does refer for weight management this may initially be a Tier 2 community 
weight management programme instead of a specialist medical or surgical 
assessment (Tiers 3 and 4).  Tier 3 is a secondary care multidisciplinary team 
approach.  Although it is mandated that patients spend between 12 to 24 months in 
a Tier 3 service before referral for surgery (Tier 4), the clinics are not available 
widely.[29,30]  The interventions offered within Tier 3 vary and outcomes are not 
routinely assessed.  Thresholds for referral on to Tier 4 are unclear and acceptance 
criteria for surgery also vary between regions, based on BMI level.[20, 31]  Some Tier 
3 clinics mandate weight loss as a qualifying threshold for surgery although evidence 
for this is absent.[32,33]  This prolonged pathway may create inertia and put 
patients off access to effective surgical treatment.[29, 31, 32] 
 
There are no current contractual mandates to fund Tier 3 clinics and from April 2016 
local commissioning groups will be free to pursue other obesity treatment strategies 
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if they prefer (and GPs will still not be able to refer directly to Tier 4 surgical 
services).  Without a clear mechanism to surgery (via Tier 3 services) then access to 
surgery may stop.   
 
The number of patients agreed by commissioners for surgery is also severely 
rationed, despite the evidence of early cost saving.  This may be because it is 
necessarily an upfront cost, with savings being recouped in a subsequent financial 
year when medication costs reduce.  Therefore, indicative numbers of procedures 
set in each region historically appear to have been determined by tokenism rather 
than any estimate of clinical need or benefit.  Considerable patient and surgeon 
advocacy has not succeeded in increasing the funding available. 
 
There also remains a popular perception amongst patients, healthcare workers and 
the media that surgery is high risk.  This is despite Hospital Episode Statistics that 
show a 30-day mortality of 1.7 in 1,000 patients, lower than many more common 
gastrointestinal operations.[34] 
 
Currently little is known about the effect of prejudice on provision of services.  One 
study from the US showed that by changing the name of a bariatric clinic to one that 
offered ‘metabolic and diabetes surgery’ as opposed to ‘bariatric surgery’ increased 
the number of male patients.[35]  The elephant in the room is that some healthcare 
workers share societal, implicit beliefs that patients with obesity are lazy and 
bad.[36]  If encouragement to diet and exercise fails there may be an assumption 
that patients have not tried hard enough; they are to blame for their predicament 
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and do not deserve surgery.  Further challenges are the either/or distinction made 
by some between prevention and treatment, and the strong views of those 
diametrically opposed to surgery.  Treating a disease does not prohibit the 
prevention of subsequent patients developing the disease.  Good examples include 
the widespread provision of complex and expensive treatments for other conditions 
caused by lifestyle issues, such as smoking related disease and road accidents, 
without any detriment to effective prevention programs.  No healthcare worker (or 
member of the public) would argue that it is inappropriate to treat the victims of a 
car crash even if the driver was later found to be over the legal limit for alcohol – but 
prejudice is commonplace and blatant in bariatric/metabolic surgery (Box 1). 
 
Which patients should be offered surgery? 
If every patient fulfilling the NICE criteria wanted surgery it would be logistically 
impossible to operate on them all.  Thus, a choice could reasonably be made to 
prioritise those with the greatest potential to have improved health outcomes to 
justify surgery.  Operating on patients who have obesity related diseases that are 
expensive to treat (high direct healthcare costs), and who have a strong likelihood of 
reducing expensive medications afterwards, makes type 2 diabetes an obvious 
priority for healthcare providers.  This view is strongly supported by NICE, as 
operating on patients with diabetes of more recent onset would lead to higher 
remission rates, and most prospective longitudinal studies suggest that patients with 
diabetes or prediabetes benefit most.[4, 11]  Alternatively, given the very large 
number of patients in this category, priority might be given to those with established 
microvascular complications, as it is not controversial that many of these patients 
12 
 
 
despite best pharmacological care will progress to become more unwell while 
simultaneously becoming more expensive.[37]  Currently it is not known whether it 
is more cost effective to operate on patients with more recent onset diabetes 
compared to those with disease of longer duration, due to the latter having greater 
medication costs before surgery.  Another option is for the multi-disciplinary team to 
decide on individual need – for instance a patient with sleep apnoea falling asleep at 
work or needing urgent weight loss pending kidney transplant.[29] 
 
As the rate of surgery in Sweden is static, we propose that the Swedish experience 
could be used as a starting point for benchmarking capacity in the NHS, where the 
equivalent rate of surgery is about 50,000 procedures a year for a population of 64 
million (Box 3).  If the operations were confined to people with a BMI of 40 kg/m2 or 
more (1.6 million), or the 20-30% of obese type 2 diabetics with microvascular 
disease (0.5 million), this would still only be 3.1% or 10% of the available population, 
respectively.  Even operating on this small proportion could make a major positive 
impact on patient health and improve direct healthcare expenditure within 2 years, 
in addition to cost savings in the future from reduced treatment costs.[13, 37] 
 
What needs to happen to increase rates of bariatric surgery? 
Based on the current evidence for the effectiveness of bariatric surgery there is a 
need to make it mainstream for people who have biological susceptibilities which 
increase their chances of becoming ‘victims’ of the modern obesogenic 
environment.[38]  At every level of care all health workers need to leave prejudice 
behind, promote bariatric surgery and offer this to people who are unable to 
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succeed with non-operative measures.  We recommend service improvement 
initiatives to overcome the barriers such as those used to improve cancer services.  
Examples might include provision of i) communication skills workshops for staff, ii) 
increased dietetic services, iii) investment into multi-disciplinary team working, and 
iv) creation of metrics to use for quality assessment with external peer review panels 
(as per the NHS Cancer Plan).  Adopting the phrase ‘metabolic surgery’ might enable 
society and patients to talk about it and begin to establish a culture change.  
 
In addition to the above recommendations, there is a need for GPs and 
commissioners to recognise the health benefits gained from bariatric surgery 
provision (and the cost savings).  This will facilitate service provision.  Particular 
concerns are the current Tier 3 and 4 services, which are often disparate.  The 
current lack of co-ordination between these services and absence of national 
outcomes data from Tier 3 clinics mean that their value and role are poorly 
understood at present.  We recommend provision of a combined Tier 3/4 service 
(with multi-disciplinary leadership) in surgical centres, and networks of Tier 3 
services linked to Tier 4 care in a monitored and pre-agreed pathway.[27]  This will 
mean that patients have access to surgical assessment earlier (as advocated by NICE 
for diabetes) and that outcomes of all interventions can be examined with teams 
working together to optimize care. 
 
How would the NHS cope with the extra work?   
Provision of more surgery goes hand in hand with the need for better long-term 
support and nutritional follow up (key to the success of surgery).  Increased surgery 
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will therefore affect primary and secondary care.  Within the UK, there is national 
variation in provision of surgery, with no NHS bariatric surgery being provided in 
Northern Ireland, and very little in Wales and Scotland.[4]  In these countries we 
recommend that new surgical services are developed. 
 
For most areas, however, there is a need for surgeons and GPs to re-prioritise and 
ensure that care for obese patients is provided and this may mean that some 
conditions are disinvested in (eg surgery for low risk gall stone disease, inguinal and 
hiatus hernias).  Active development of ‘obesity’, or ‘metabolic’ care for surgical 
follow up in general practice could be utilised (with incentives) to improve care 
simultaneously for obese people not wanting surgery.  It is possible that a renewed 
active focus on this very large group of patients will limit future costs of treating 
obesity and diabetes related complications.  
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Legends to figures  
 
Figure 1.  The cost of obesity and diabetes is threatening to overwhelm healthcare 
systems, but prejudice against treating ‘victims’ of both epidemics is widespread and 
very few receive bariatric surgery, a clinically effective and cost saving treatment. 
 
Figure 2.  By contrast, immediate and long-term care is provided unquestioningly for 
car crash victims, irrespective of cause.  A new paradigm in healthcare is needed to 
match this care for the obese. 
 
Figure 3. Pathways and barriers to surgery and estimated numbers relevant to each 
stage of the system.  The tiers refer to the structure of obesity care with the NHS.  
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Key messages – Text box 1   
 
Severe and complex obesity, defined as a body mass index (BMI) of at least 40 
kg/m2 or a BMI of 35 kg/m2 if there is obesity related disease, is a serious public 
health issue which requires active investment and appropriate healthcare 
services (Figure 1) 
 
The perception that the condition is self-inflicted should not prohibit provision of 
urgent care and effective interventions such as bariatric surgery  
 
Major surgery and support is routinely (without question) provided for victims of 
road traffic accidents – whatever the cause of the incident (Figure 2)  
 
There is a need to rethink approaches to people with severe obesity and to 
provide urgent interventions to lead to weight loss and reduction of obesity 
related disease 
 
Simultaneous (non-surgical) public health interventions are required to prevent 
people who are overweight and obese becoming severely obese and in need of 
surgery. 
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Key messages – Text box 3 
 
Bariatric surgery associated with careful follow up is effective and cost-effective 
for the treatment of severe obesity and type 2 diabetes 
 
Despite clear NICE guidance and recommendations for surgery it is provided for 
much less than 1% of those who could benefit from it in the UK and the rate is 
decreasing 
 
Widespread variation exists in access to bariatric surgery and this affects males 
and minority ethnic groups 
 
The best patient to operate on for economic return of initial outlay is unknown.  
It is possible that patients on multiple medications and requiring self-monitoring 
of blood glucose for type 2 diabetes may optimally benefit 
 
Increasing the rate of surgery from around 6,000 to 50,000 cases per annum 
would bring the UK in line with other western European countries with similar 
healthcare systems 
 
There is a need for close co-ordination of surgical, medical and primary care 
obesity services to select and support patients for surgery and provide follow up 
Key messages – Text box 2 Summary of updated NICE Guidance CG 189 bariatric 
surgery recommendations (2014) 
 
Offer an expedited assessment for bariatric surgery to people with a BMI of 35 
kg/m2 or more with onset of type 2 diabetes within 10 years 
  
Consider an assessment for bariatric surgery for people with a BMI of 30-34.9 
kg/m2 with onset of type 2 diabetes within 10 years 
  
Consider an assessment for bariatric surgery for people of Asian origin with onset 
of type 2 diabetes at a lower BMI than other populations 
  
Bariatric surgery is the option of choice for adults with BMI of more than 50 
when other interventions have not been effective 
 
People fitting all of the above criteria are also required to be receiving or to 
receive assessment in a Tier 3 specialist weight management service (or 
equivalent) before referral to a surgical team (Tier 4) 
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